Cargando…
Characterization of More Selective Central Nervous System Nrf2-Activating Novel Vinyl Sulfoximine Compounds Compared to Dimethyl Fumarate
The Nrf2 transcription factor is a key regulator of redox reactions and considered the main target for the multiple sclerosis (MS) drug dimethyl fumarate (DMF). However, exploration of additional Nrf2-activating compounds is motivated, since DMF displays significant off-target effects and has a rela...
Autores principales: | Carlström, Karl E., Chinthakindi, Praveen K., Espinosa, Belén, Al Nimer, Faiez, Arnér, Elias S. J., Arvidsson, Per I., Piehl, Fredrik, Johansson, Katarina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7609514/ https://www.ncbi.nlm.nih.gov/pubmed/32394330 http://dx.doi.org/10.1007/s13311-020-00855-0 |
Ejemplares similares
-
Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes
por: Carlström, Karl E., et al.
Publicado: (2019) -
Persistence with dimethyl fumarate in relapsing-remitting multiple sclerosis: a population-based cohort study
por: Eriksson, Irene, et al.
Publicado: (2017) -
The use of chiral lithium amides in the desymmetrisation of N-trialkylsilyl dimethyl sulfoximines
por: McGrath, Matthew J, et al.
Publicado: (2007) -
The NRF2 pathway as potential biomarker for dimethyl fumarate treatment in multiple sclerosis
por: Hammer, Anna, et al.
Publicado: (2018) -
Dimethyl Fumarate Ameliorates Doxorubicin-Induced Cardiotoxicity By Activating the Nrf2 Pathway
por: Hu, Xiaoliang, et al.
Publicado: (2022)